The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
FRONTiER: A feasibility trial of nivolumab with neoadjuvant CF or DCF therapy for locally advanced esophageal carcinoma (JCOG1804E)—The short-term results of cohort A and B.
 
Shun Yamamoto
No Relationships to Disclose
 
Ken Kato
Honoraria - Bristol-Myers Squibb; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Research Funding - Beigene (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst)
 
Hiroyuki Daiko
No Relationships to Disclose
 
Takashi Kojima
Honoraria - Oncolys BioPharma; Ono Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Merck; MSD; Ono Pharmaceutical
Research Funding - Astellas Amgen BioPharama (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Hiroki Hara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; MSD; Ono Pharmaceutical; Sanofi; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Lilly; MSD; Ono Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Incyte (Inst); LSK BioPharma (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst)
 
Tetsuya Abe
No Relationships to Disclose
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Takeo Fujita
No Relationships to Disclose
 
Takashi Fukuda
No Relationships to Disclose
 
Shigenori Kadowaki
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Eisai; Lilly; Merck KGaA; Ono Pharmaceutical; Yakult Pharmaceutical
Research Funding - Chugai Pharma (Inst); Lilly (Inst); MSD (Inst); Nobelpharma (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takahiro Tsushima
Honoraria - Bayer; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
 
Yasuo Hamamoto
Consulting or Advisory Role - Chugai Pharma; Dainippon Sumitomo Pharma
Research Funding - Bristol-Myers Squibb Japan; Lilly Japan; MSD Oncology; Ono Pharmaceutical
 
Kengo Nagashima
Consulting or Advisory Role - Fujimoto; Senju Pharmaceutical; Toray Industries
Speakers' Bureau - Pfizer
 
Kazunori Aoki
Research Funding - Eisai; Ono Pharmaceutical; Otsuka
 
Yukihiro Mizoguchi
No Relationships to Disclose
 
Shigehisa Kitano
Honoraria - AstraZeneca; AYUMI; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; GlaxoSmithKline; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Chugai Pharma; Eisai; MSD; Novartis; Ono Pharmaceutical
Research Funding - Astellas Pharma; Astellas Pharma; Boehringer Ingelheim; Daiichi Sankyo; Eisai; Gilead Sciences; Ono Pharmaceutical; REGENERON; Takara Bio
 
Shinichi Yachida
No Relationships to Disclose
 
Satoshi Shiba
No Relationships to Disclose
 
Yuko Kitagawa
Honoraria - Asahi Kasei; Astellas Pharma; Chugai Pharma; Dainippon Sumitomo Pharma; EA Pharma; Eisai; Kaken Pharmaceutical; Nihon Pharma; Ono Pharmaceutical; Otsuka; Otsuka; Sanofi; Shionogi; Taiho Pharmaceutical; Taisho Toyama Pharma; Yakult Honsha
Research Funding - Asahi Kasei (Inst); Astellas Pharma (Inst); Chugai Pharma (Inst); Dainippon Sumitomo Pharma (Inst); EA Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Medicon (Inst); Nihon Pharma (Inst); Nippon Covidien (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); Toyama Chemical Co (Inst); TSUMURA & CO. (Inst); Yakult Honsha (Inst)